test group:iparomlimab and tuvonralimab (QL1706)

2 trials

Sponsors

The Second Affiliated Hospital of Guangxi Medical University, Qilu Hospital of Shandong University

Conditions

Advanced HER2-negative gastric cancer with low PD-L1 expressionPatients with resectable locally advanced esophageal squamous cell carcinoma (clinical stage III-IVa)

Early Phase 1

A Prospective, Single-Arm, Phase II Clinical Study of iparomlimab and tuvonralimab (QL1706) Combined with Platinum-Based Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

Active, not recruitingChiCTR2500105213

The Second Affiliated Hospital of Guangxi Medical UniversityPatients with resectable locally advanced esophageal squamous cell carcinoma (clinical stage III-IVa)

Start: 2025-07-01Updated: 2025-07-07

Phase 2

Phase II Trial of Iparomlimab/Tuvonralimab (QL1706) + XELOX in HER2-Negative, Low PD-L1 G/GEJ Adenocarcinoma (SEARCH)

RecruitingChiCTR2500106716

Qilu Hospital of Shandong UniversityAdvanced HER2-negative gastric cancer with low PD-L1 expression

Start: 2025-04-27Updated: 2025-08-18